# Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors

> **NCT02108782** · PHASE2 · WITHDRAWN · sponsor: **Academic and Community Cancer Research United**

## Conditions studied

- Gastrinoma
- Glucagonoma
- Insulinoma
- Pancreatic Polypeptide Tumor
- Recurrent Islet Cell Carcinoma
- Somatostatinoma

## Interventions

- **DRUG:** dovitinib lactate
- **OTHER:** pharmacological study
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT02108782
- **Lead sponsor:** Academic and Community Cancer Research United
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2014-10
- **Primary completion:** 2015-05
- **Final completion:** 2015-05
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2017-07-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02108782

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02108782, "Dovitinib Lactate in Treating Patients With Pancreatic Neuroendocrine Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02108782. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*